introduction 2-[Fluorine-18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) has been an exciting development in recent years, providing accurate functional information as well as anatomical information when combined with computed tomography (CT). Since its first application in cancer imaging in 1993 [1] , PET has demonstrated a significant benefit in the management of a number of malignancies.
In breast cancer, the role of PET is not clearly defined. Several efficient imaging tools including mammography, magnetic resonance imaging (MRI), bone scans (BS) and CT scans are widely available, making the implementation of yet another modality a challenging process. Published data suggest that PET is not reliable in evaluating the primary tumour or accurately staging the axillary disease. In primary staging, PET has been shown to be inferior to conventional imaging because of its low accuracy and its association with noticeable numbers of false-negative results [2] . For similar reasons, its utility in axillary nodal assessment is limited [3] [4] [5] [6] and it cannot replace histopathological staging (sentinel node biopsy/axillary dissection) that remains the gold standard.
However, PET appears to be sufficiently sensitive and specific in detecting disease recurrence [7] [8] [9] [10] [11] . One of the few prospective studies in this setting [7] investigated the outcomes of PET and MRI in 32 patients with locoregional recurrence. The sensitivity and specificity of the two scans were 100% and 79%, and 72% and 94%, respectively. Other studies have specifically looked at the role of PET in cases where the clinical suspicion of metastatic disease was high or tumour markers were rising. In one study [12] , of 46 patients with rising tumour markers, 65% had tumour recurrence that was confirmed by PET/CT, with sensitivity of 90%, specificity of 71% and accuracy of 83%.
The greatest application of PET and PET/CT in clinical practice at present is assessing metastatic disease. Its diagnostic performance for detecting metastatic disease has been reported in terms of sensitivity between 84% and 93% [7, 8, 12] . Its superiority is particularly related to assessing small sites of nodal disease and bone metastases [13] [14] [15] [16] . In a study by Bender et al. [17] , PET correctly identified 28 (97%) of 29 patients with lymph node involvement, 15 (100%) of 15 patients with bone metastases, 5 (83%) of 6 patients with lung metastases and 2 (100%) of 2 patients with liver metastases. The superiority of PET over bone scanning in demonstrating osteolytic metastases was demonstrated by Cook et al. [18] about a decade ago and has been confirmed by more recent data [19] on PET/CT. BS appears to maintain better sensitivity for osteoblastic metastases and some investigators suggest that the two scans should have complementary roles [20, 21] .
PET also appears to have a role in assessing response to systemic therapy [22] . In the neoadjuvant setting, PET allows early identification of non-responders or chemotherapyresistant patients determining timing for surgery [23] . In the metastatic setting, it contributes to management optimisation by allowing termination of costly or toxic therapies in nonresponders. It might also be useful in predicting response to treatment as it detects metabolic changes that usually precede anatomical changes [24] . Clarification of equivocal lesions is another area where the contribution of PET/CT has been noticeable [7] . It appears to be effective in differentiating malignant from non-malignant lesions when they are equivocal or not well defined on conventional imaging.
The majority of these data arise from small largely retrospective studies that predominately assessed PET alone and not in combination with CT (PET/CT). While data from randomised trials are awaited, the use of PET in clinical practice in the UK and worldwide is sparse depending on the availability of the scanner, the availability of funding and the clinician's personal understanding of the applicability of PET. The aims of this large retrospective study were to identify the areas where PET/CT had been beneficial either as a single modality or in comparison with conventional imaging when used in our institution and to ascertain its contribution in optimising management. Such information is essential for formulating guidelines for the appropriate use of PET imaging.
patients and methods
We reviewed PET/CT scans carried out in breast cancer patients in our institution from July 2004 to October 2008 and the corresponding electronic the corresponding electronic patient records (EPR). Cases where patient information was incomplete or where PET/CT images were unavailable were not included in the analysis. A number of patients had >1 PET/CT scan during this period and each scan was considered a separate case. In each case, we determined the indication for the scan, the result, concordance/discordance with other imaging modalities and whether the use of PET/CT had altered patient management. In the majority of cases, patients had baseline PET/CT scans before starting chemotherapy, interim scans after three cycles and end of treatment scans after six cycles. In some occasions, PET/CT was carried out after two cycles on suspicion of disease progression.
Patients were scanned on either Siemens' Biograph LSO PET/CT or GE Discovery VCT BGO scanners. On average, 370 MBq 18-F-FDG was injected with a 60-min patient uptake time (patients under comfortable resting conditions). Imaging was routinely carried out from the base of the skull to the upper thighs; on occasion, where indicated, the cranium was included in the acquisition. Data were analysed by dual-trained Oncological Radiology/Nuclear Medicine Consultants. Data were visually analysed on workstations and standardised uptake value analysis was also carried out when required, particularly for response evaluation. European Organisation for Research and Treatment of Cancer criteria were used for metabolic response evaluation. RECIST criteria were used in terms of correlative anatomical CT aspects of PET/CT. CT and MRI results were derived from patients' records.
statistical analysis
Summary statistics were calculated for different patients' subgroups. Proportions (%) of patients in each category were used for categorical variables.
patient characteristics
Two hundred and thirty-three PET/CT scans carried out in 122 breast cancer patients were reviewed. The majority of patients (90%) had invasive ductal carcinoma. Forty-seven patients (39%) had >1 PET/CT scan. One hundred and sixty-eight scans (72%) were carried out in patients with recurrent or metastatic disease. 
PET/CT results
Staging recurrent/metastatic disease. The main indication for carrying out PET/CT scans was high clinical suspicion (signs or symptoms) of recurrence or progression (n = 35/91, 38%), followed by staging before initiation/change of systemic treatment (n = 14/91, 15%) and tumour marker rise (n = 11/91, 12%). All indications are shown in Table 1 .
In the majority of cases (56/91, 62%), PET/CT was the only scan carried out for staging. In the remaining cases (38%), other scans (CT, MRI and BS) were carried out just before or after PET/CT. In cases where PET/CT was carried out to exclude spread of the disease following an intervention (surgery/radiotherapy/gamma-knife) to a solitary metastatic site, no other scans were carried out. PET/CT was also the only scan carried out in the majority of cases where the indication was signs suggestive of recurrence or tumour marker rise. All the results are shown in Table 1 . 
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While in the majority of cases (65%) the results of PET/CT were in agreement with those of CT, in five cases (29%), PET/ CT revealed more sites of disease than CT alone. In two cases, the PET/CT showed bone lesions that were not identified on CT. In the third case, PET/CT showed lymphadenopathy in multiple areas, while CT showed lymphadenopathy in one area only, and in the fourth case, while the CT showed axillary thickening only, the PET showed local recurrence and axillary lymphadenopathy. In the fifth case, the PET/CT showed small volume but widely spread FDG avid disease involving the lung, liver, mesentery, bone and lymphadenopathy, whereas the CT showed lung metastases only. The MRI results were identical with the PET/CT results in 78% of cases. With regard to the BS, in 70% of cases, the results were in agreement with the PET/CT. In all three cases (30%) of disagreement, PET/CT identified a lytic lesion that was missed on BS (false negative).
response assessment. Systemic treatment comprised chemotherapy with or without targeted agents for more than 66% (58/87) of patients, hormonal therapy for 20% (18/87) of patients and targeted therapy alone for 8% (7/87). Four patients (6%) were treated in the context of a phase I trial.
The commonest sites of metastatic disease identified on PET/ CT included lymphadenopathy (57/87, 65%), bone (50/87, 57%), liver (36/87, 41%) and lung (31/87, 36%) metastases. In some cases, changes in the PET FDG uptake (decrease) suggesting response to treatment preceded the anatomical changes documented on the CT component of the scan. This occurred in 14% of cases with nodal metastases, in 18% of cases with bone metastases, in 18% of cases with lung metastases and in 11% of cases with liver metastases. PET/CT showed a complete response in 2 cases (2%), partial response in 36 cases (41%), stable disease in 23 cases (26%), progressive disease in 18 cases (21%) and mixed response in 8 cases (9%).
In the majority of cases, interim imaging for RA was carried out after three cycles of chemotherapy and 3 months of hormonal treatment. The end of treatment scan for chemotherapy was carried out after six cycles. However, early RA (after two cycles of chemotherapy or 2 months of hormonal treatment) was carried out in 15% of cases. Of those, in 30%, treatment was discontinued early due to disease progression.
clarification. PET/CT was used for the clarification of equivocal lesions (n = 12) or lesions that had doubtful significance despite being fairly confidently reported as malignant on other imaging (n = 20). They included lesions in the liver, bone, lung, nodes and brachial plexus. In 4 cases, three imaging tests (CT, MRI and BS) had been carried out before PET/CT; in 6 cases, two imaging tests had been carried out and in the rest of cases (22) , one test had been carried out. Among these cases, 19 (59%) were negative on PET/CT, 5 (16%) partially confirmed the findings, 4 (12%) confirmed all findings and 3 (9%) did not confirm the indication but showed other sites of metastatic disease. All the results are shown in Table 2 . With regard to concordance/discordance with the BS (N = 13) in 46% (6/13) of cases, PET/CT and BS were discordant and in 38% of cases, they were concordant (5/13). No lytic lesions were observed in any of these cases. In the remaining two cases (15%) where the findings in the BS were equivocal, PET/CT showed no evidence of increased metabolic activity. The details are outlined in Table 2 . With regard to MRI (N = 15), all cases with equivocal (53%) lesions on MRI showed no significant metabolic activity on PET/CT. Twenty percent were discordant and 27% were concordant. With regard to CT (N = 18), 17% were concordant, 39% were discordant and 50% of the equivocal lesions were negative on PET/CT. In one case where CT showed indeterminate lung lesions, PET/CT showed low-grade FDG avidity, failing to determine whether they were metastatic or not.
reassurance. In the ASS group, most patients presented with non-specific symptoms (symptoms that could be attributed to benign causes and were not obviously suggestive of disease recurrence) and had PET/CT scans to exclude recurrence of their disease. All scans in this group were negative.
Examples of cases where the contribution of PET/CT in altering management was significant are shown in Table 3 . In a significant number of cases, PET/CT helped determine whether the management setting was curative or palliative.
discussion
The lack of recommendations to guide appropriate use of PET/ CT imaging is one of the factors limiting its application in breast cancer. The introduction of guidelines requires sufficient evidence demonstrating that PET/CT is at least equivalent if not superior to other imaging modalities currently available. The results of this study confirm that there is a role for PET/CT in certain areas of breast cancer assessment and treatment.
The strengths of PET are well recognised. It is a whole-body scan that allows the visualisation of metabolic changes that usually precede anatomical changes; it is more sensitive than and equally specific to other imaging modalities in detecting small lesions (5-10 mm), particularly lymph nodes as well as visceral and bone disease. CT has a distinct advantage in detecting small lung and liver metastases. In combination, they provide an imaging tool with higher sensitivity and special resolution that could potentially replace conventional imaging in at least some aspects of breast cancer management.
A significant proportion of patients in this study had PET/CT scans for staging in the recurrent and metastatic setting. Interestingly when the clinician felt the indication for recurrence or progression was fairly strong (signs suggesting recurrence or tumour marker rise), PET/CT was the only imaging modality carried out, in the majority of cases (Table 1) . When performed alongside other imaging modalities (CT, MRI and BS), PET/CT provided accurate assessment of the metastatic disease. In some cases, it revealed more metastatic sites than identified on CT. It was more accurate than BS in detecting metastatic osteolytic disease. To date, early detection of recurrent/metastatic disease by conventional imaging does not appear to have an impact on overall survival but allows initiation of treatment before the development of severe symptoms or their progression. The addition of promising targeted and endocrine agents to the treatment arena, however, might improve survival rates and early detection is becoming increasingly important. In this context, PET/CT can be particularly useful because of its ability to demonstrate disease early, even when the tumour burden is small.
One of the important findings in this study is that PET/CT is useful in accurate assessment of response to chemotherapy and hormonal therapy as there is a strong relationship between response and decrease in FDG signal even at an early stage of No significant FDG uptake in liver/pleural but increased in axillary and mediastinal LNpathy BS, bone scan; C, concordant; CT, computed tomography; D, discordant; IMC, infra-mammary chain; LNpathy, lymphadenopathy; met(s), metastasis(es); MRI, magnetic resonance imaging; PET/CT, positron emission tomography/computed tomography; SCF, supra-clavicular fossa; tx, treatment; USS, ultrasound.
Annals of Oncology original article therapy. In breast cancer, it is particularly important to differentiate responders from non-responders at an early stage for two reasons. On one hand, to avoid unnecessary treatment toxicity and on the other hand to change the therapeutic regimen to a potentially more effective one as contrary to other malignancies, in breast cancer the treatment options are not limited. In our study, one-third of the scans were performed with this indication, suggesting that clinicians find this application useful. In a significant number of cases, metabolic changes were documented earlier than the anatomical changes, confirming the role of PET in early identification of response. In some cases, the early detection of disease progression on PET/CT resulted in the appropriate discontinuation of ineffective, costly and potentially toxic treatment. The contribution of PET/CT to management optimisation was evident when it was used for the clarification of lesions on other imaging. PET/CT was negative in 60% of cases where conventional imaging was suggestive of disease. In particular, the lesions (suspicious or equivocal) on over half of the BS were not significantly metabolically active on PET/CT. Similarly, all lesions reported as equivocal on MRI were negative on PET/CT. In some of these cases, unnecessary treatment was avoided as a result of the PET/CT result. Conversely, appropriate local treatment (surgery and radiotherapy) was administered where PET/CT showed absence of metastatic disease and systemic treatment was given when PET/CT demonstrated (otherwise undetected) metastatic disease. In some cases, PET/CT defined the intent of treatment (curative versus palliative) by accurately delineating the sites of disease.
The retrospective nature of this study and the fact that all patients were managed in the same institution constitute its main limitations. The aim of this study was not to determine the diagnostic value of PET/CT against histopathology or other imaging tests but to assess and report our current practice so as to ensure the appropriate use of PET/CT in breast cancer management in our institution. To that end, the results of the study are in line with those of other similar retrospective studies [25, 26] . The main difference is that this represents the largest series of PET/CT scans and one of the largest series of PET scans published to date.
While the results of randomised studies on different aspects of the utility of PET in breast cancer are awaited, simple recommendations on its use in everyday practice are necessary. Based on the results of this study, PET/CT may be used as the first-line investigation in patients with recurrent/metastatic breast cancer instead of a number of serial investigations. Given its ability for early evaluation of metabolic changes, it can be used for treatment response assessment. When lytic bone metastatic disease is suspected, PET/CT should be used instead of BS.
In conclusion, PET/CT may be useful in staging recurrent/ progressive metastatic disease. It is more accurate than BS in detecting metastatic lytic bone disease. It may be used in assessing response to treatment and can result in early termination of treatment in non-responders. By clarification of lesions on other imaging, PET/CT may contribute to management optimisation either by allowing administration of appropriate treatment or by preventing unnecessary treatment. The appropriate use of this modality can help tailor and optimise treatment of the individual patient. More prospective randomised trials will ascertain its role in every area of breast cancer management.
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